Skip to contents

Mohammad Kian Salajegheh, MD
Associate Neurologist, Brigham and Women's Hospital
Assistant Professor of Neurology, Harvard Medical School

Brigham and Women's Hospital
Department of Neurology
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:
My research has focused on muscle diseases and primarily inflammatory myopathies (basic research) and muscle channelopathies (clinical research), in addition to involvement with clinical studies on stiff person syndrome, neuropathies, myasthenia gravis and motor neuron disease.
 
My main interest in the area of inflammatory myopathies has been on inclusion body myositis (IBM) and to some extent dermatomyosits (DM):
·         Presence of antigen driven T-cell response (spectrayping of the T cell receptor in muscle compared with blood).
·         Presence of antigen driven B-cell response (using laser capture microdissection).
·         Abnormal redistribution of TDP-43 in IBM muscle. Currently used as one of the pathologic diagnostic findings in IBM.
·         Nature of “tau” immunoreactivity in muscle of patient with IBM.
·         Presence of highly specific serum reactivity against a 40-44 kDa muscle protein in IBM blood with support from a development grant from the MDA. (prior PI)
·         Identification of Nt5C1A (5'-nucleotidase cytosolic IA) as one of the target antigens of immunoreactivity in IBM. Now offered as a diagnostic blood test for IBM.
·         Currently continuing my research under an R03 grant from NIAMS/NIH to identify other antigens in IBM. (current PI).
·         Understanding atrophy pathways in IBM and the importance of SMAD2/3 phosphorylation. Based on this study a pilot clinical trial using BYM338 (anti ActRIIb receptor, preventing binding of myostatin) has been completed and moving on to a phase 2b/3 trial. (current-CoI)
·         Understanding atrophy pathways in DM and role of the up-regulation of the ISG15 conjugation pathway in perifascicular atrophy.
·         Clinical trial of MEDI-545 in DM and PM (current CoI).
·         Clinical trial of BAF312 (sphingosine 1-phosphate receptor modulator) in DM and PM (current CoI).
 
Regarding muscle channelopathies I have done limited bench research and have placed my focus on natural history studies and clinical trials:
·         Studied a mouse model of hyperkalemic periodic paralysis and the effects of alterations in electrolytes on muscle strength.
·         Natural history of myotonic disorders and Andersen-Tawil syndrome (prior CoI)
·         Treatment of periodic paralyses with acetazolamide and dichlorphenamide (both carbonic anhydrase inhibitors) (prior CoI)
·         Trial of mexiletine in non-dystrophic myotonias (prior site-PI)
 
Other activities:
·         International GBS outcome study (current site-PI).
·         Thymectomy in myasthenia gravis ( current CoI).
·         Rituximab in IgM MGUS anti-MAG neuropathies (prior CoI).
·         Natural history study of stiff person syndrome (prior CoI).
·         Trial of modafinil in post-polio syndrome (prior CoI).

Education:
MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Ting BL, Blazar PE, Collins JE, Mora AN, Salajegheh MK, Amato AA, Earp BE. Median Nerve Ultrasonography Measurements Correlate With Electrodiagnostic Carpal Tunnel Syndrome Severity. J Am Acad Orthop Surg. 2019 Jan 01; 27(1):e17-e23.

2. Salajegheh MK, Domingo-Horne RM. The Reply. Am J Med. 2018 Nov; 131(11):e485.

3. Foster LA, Salajegheh MK. Motor Neuron Disease: Pathophysiology, Diagnosis, and Management. Am J Med. 2019 Jan; 132(1):32-37.

4. Domingo-Horne RM, Salajegheh MK. An Approach to Myopathy for the Primary Care Clinician. Am J Med. 2018 Mar; 131(3):237-243.

5. Graham B, Peljovich AE, Afra R, Cho MS, Gray R, Stephenson J, Gurman A, MacDermid J, Mlady G, Patel AT, Rempel D, Rozental TD, Salajegheh MK, Keith MW, Jevsevar DS, Shea KG, Bozic KJ, Adams J, Evans JM, Lubahn J, Ray WZ, Spinner R, Thomson G, Shaffer WO, Cummins DS, Murray JN, Mohiuddin M, Mullen K, Shores P, Woznica A, Linskey E, Martinez Y, Sevarino K. The American Academy of Orthopaedic Surgeons Evidence-Based Clinical Practice Guideline on: Management of Carpal Tunnel Syndrome. J Bone Joint Surg Am. 2016 Oct 19; 98(20):1750-1754.

6. Hahn C, Salajegheh MK. Myotonic disorders: A review article. Iran J Neurol. 2016 Jan 05; 15(1):46-53.

7. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8.

8. Quinn C, Salajegheh MK. Myotonic Disorders and Channelopathies. Semin Neurol. 2015 Aug; 35(4):360-8.

9. O'Neal MA, Chang LY, Salajegheh MK. Postpartum spinal cord, root, plexus and peripheral nerve injuries involving the lower extremities: a practical approach. Anesth Analg. 2015 Jan; 120(1):141-8.

10. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014 Dec 09; 83(24):2239-46.